BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sheyhidin I, Nabi G, Hasim A, Zhang RP, Ainiwaer J, Ma H, Wang H. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol 2011; 17(32): 3745-3751 [PMID: 21990957 DOI: 10.3748/wjg.v17.i32.3745] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 64] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Yang L, Francois F, Pei Z. Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res. 2012;18:2138-2144. [PMID: 22344232 DOI: 10.1158/1078-0432.ccr-11-0934] [Cited by in Crossref: 93] [Cited by in F6Publishing: 63] [Article Influence: 9.3] [Reference Citation Analysis]
2 Lim K. TLR9. In: Marshall JL, editor. Cancer Therapeutic Targets. New York: Springer; 2017. pp. 495-502. [DOI: 10.1007/978-1-4419-0717-2_70] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Wu K, Yang Y, Liu D, Qi Y, Zhang C, Zhao J, Zhao S. Activation of PPARγ suppresses proliferation and induces apoptosis of esophageal cancer cells by inhibiting TLR4-dependent MAPK pathway. Oncotarget 2016;7:44572-82. [PMID: 27323819 DOI: 10.18632/oncotarget.10067] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
4 Ni YH, Ding L, Zhang DY, Hou YY, Huang X, Hu Q. Distinct expression patterns of Toll-like receptor 7 in tumour cells and fibroblast-like cells in oral squamous cell carcinoma. Histopathology 2015;67:730-9. [DOI: 10.1111/his.12703] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
5 Verbeek RE, Siersema PD, Ten Kate FJ, Fluiter K, Souza RF, Vleggaar FP, Bus P, van Baal JW. Toll-like receptor 4 activation in Barrett's esophagus results in a strong increase in COX-2 expression. J Gastroenterol 2014;49:1121-34. [PMID: 23955118 DOI: 10.1007/s00535-013-0862-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
6 Ilmarinen T, Hagström J, Haglund C, Auvinen E, Leivo I, Pitkäranta A, Aaltonen LM. Low expression of nuclear Toll-like receptor 4 in laryngeal papillomas transforming into squamous cell carcinoma. Otolaryngol Head Neck Surg 2014;151:785-90. [PMID: 25205638 DOI: 10.1177/0194599814549730] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
7 Rossi AH, Farias A, Fernández JE, Bonomi HR, Goldbaum FA, Berguer PM. Brucella spp. Lumazine Synthase Induces a TLR4-Mediated Protective Response against B16 Melanoma in Mice. PLoS One 2015;10:e0126827. [PMID: 25973756 DOI: 10.1371/journal.pone.0126827] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
8 Yeh DW, Huang LR, Chen YW, Huang CF, Chuang TH. Interplay between Inflammation and Stemness in Cancer Cells: The Role of Toll-Like Receptor Signaling. J Immunol Res 2016;2016:4368101. [PMID: 28116318 DOI: 10.1155/2016/4368101] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
9 Tang H, Wang F, Zhou XF, Zhou J, Chen L, Luo JD, Xu EC. Relationship between TLR4 and NF-κB p65 protein expressions and clinical radiosensitivity of patients with esophageal squamous cell carcinoma. Pak J Med Sci 2014;30:982-5. [PMID: 25225511 DOI: 10.12669/pjms.305.5472] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Kauppila JH, Selander KS. Toll-like receptors in esophageal cancer. Front Immunol 2014;5:200. [PMID: 24847326 DOI: 10.3389/fimmu.2014.00200] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
11 Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res. 2012;35:1297-1316. [PMID: 22941474 DOI: 10.1007/s12272-012-0802-7] [Cited by in Crossref: 117] [Cited by in F6Publishing: 114] [Article Influence: 11.7] [Reference Citation Analysis]
12 Helminen O, Huhta H, Lehenkari PP, Saarnio J, Karttunen TJ, Kauppila JH. Nucleic acid-sensing toll-like receptors 3, 7 and 8 in esophageal epithelium, barrett's esophagus, dysplasia and adenocarcinoma. Oncoimmunology 2016;5:e1127495. [PMID: 27467941 DOI: 10.1080/2162402X.2015.1127495] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
13 Huhta H, Helminen O, Lehenkari PP, Saarnio J, Karttunen TJ, Kauppila JH. Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma. Oncotarget 2016;7:23658-67. [PMID: 27008696 DOI: 10.18632/oncotarget.8151] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 7.5] [Reference Citation Analysis]
14 Baakhlagh S, Kashani B, Zandi Z, Bashash D, Moradkhani M, Nasrollahzadeh A, Yaghmaei M, Mousavi SA, Ghaffari SH. Toll-like receptor 4 signaling pathway is correlated with pathophysiological characteristics of AML patients and its inhibition using TAK-242 suppresses AML cell proliferation. Int Immunopharmacol 2021;90:107202. [PMID: 33278749 DOI: 10.1016/j.intimp.2020.107202] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Grimmig T, Moench R, Kreckel J, Haack S, Rueckert F, Rehder R, Tripathi S, Ribas C, Chandraker A, Germer CT, Gasser M, Waaga-Gasser AM. Toll Like Receptor 2, 4, and 9 Signaling Promotes Autoregulative Tumor Cell Growth and VEGF/PDGF Expression in Human Pancreatic Cancer. Int J Mol Sci 2016;17:E2060. [PMID: 27941651 DOI: 10.3390/ijms17122060] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
16 Patinote C, Karroum NB, Moarbess G, Cirnat N, Kassab I, Bonnet PA, Deleuze-Masquéfa C. Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. Eur J Med Chem 2020;193:112238. [PMID: 32203790 DOI: 10.1016/j.ejmech.2020.112238] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 14.0] [Reference Citation Analysis]
17 Jouhi L, Datta N, Renkonen S, Atula T, Mäkitie A, Haglund C, Ahmed A, Syrjänen S, Grénman R, Auvinen E, Lehtonen S, Hagström J. Expression of toll-like receptors in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma—an in vivo and in vitro study. Tumor Biol 2015;36:7755-64. [DOI: 10.1007/s13277-015-3494-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
18 Nihon-Yanagi Y, Wakayama M, Tochigi N, Saito F, Ogata H, Shibuya K. Immunohistochemical Analysis of Toll-Like Receptors, MyD88, and TRIF in Human Papillary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. J Thyroid Res 2021;2021:4226491. [PMID: 34306609 DOI: 10.1155/2021/4226491] [Reference Citation Analysis]
19 Liu Y, Guo X, Wu L, Yang M, Li Z, Gao Y, Liu S, Zhou G, Zhao J. Lipid rafts promote liver cancer cell proliferation and migration by up-regulation of TLR7 expression. Oncotarget 2016;7:63856-69. [PMID: 27588480 DOI: 10.18632/oncotarget.11697] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
20 Visser E, Franken IA, Brosens LAA, de Leng WWJ, Strengman E, Offerhaus JA, Ruurda JP, van Hillegersberg R. Targeted next-generation sequencing of commonly mutated genes in esophageal adenocarcinoma patients with long-term survival. Dis Esophagus 2017;30:1-8. [PMID: 28859360 DOI: 10.1093/dote/dox058] [Reference Citation Analysis]
21 Klein JC, Moses K, Zelinskyy G, Sody S, Buer J, Lang S, Helfrich I, Dittmer U, Kirschning CJ, Brandau S. Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth. Nat Commun 2017;8:14600. [PMID: 28300057 DOI: 10.1038/ncomms14600] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
22 Khan A, Khan Z, Warnakulasuriya S. Cancer-associated toll-like receptor modulation and insinuation in infection susceptibility: association or coincidence? Annals of Oncology 2016;27:984-97. [DOI: 10.1093/annonc/mdw053] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
23 Cen X, Liu S, Cheng K. The Role of Toll-Like Receptor in Inflammation and Tumor Immunity. Front Pharmacol 2018;9:878. [PMID: 30127747 DOI: 10.3389/fphar.2018.00878] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 14.3] [Reference Citation Analysis]
24 Li J, Wu H, Gao H, Kou R, Xie Y, Zhang Z, Zhang X. TLR4 promoter rs1927914 variant contributes to the susceptibility of esophageal squamous cell carcinoma in the Chinese population. PeerJ 2021;9:e10754. [PMID: 33585082 DOI: 10.7717/peerj.10754] [Reference Citation Analysis]
25 Liu J, Wang Y, Chu Y, Xu R, Zhang D, Wang X. Identification of a TLR-Induced Four-lncRNA Signature as a Novel Prognostic Biomarker in Esophageal Carcinoma. Front Cell Dev Biol 2020;8:649. [PMID: 32850794 DOI: 10.3389/fcell.2020.00649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Mokhtari Y, Pourbagheri-Sigaroodi A, Zafari P, Bagheri N, Ghaffari SH, Bashash D. Toll-like receptors (TLRs): An old family of immune receptors with a new face in cancer pathogenesis. J Cell Mol Med 2021;25:639-51. [PMID: 33336901 DOI: 10.1111/jcmm.16214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Chang L, Guo F, Lv Y, Wang Y, Huo B, Wang L, Liu W. The inhibitory effects of Endostar combined with chemotherapy on human esophageal squamous cell carcinoma xenograft in mice. Mol Biol Rep 2013;40:669-73. [PMID: 23054020 DOI: 10.1007/s11033-012-2106-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
28 De Schutter T, Andrei G, Topalis D, Duraffour S, Mitera T, van den Oord J, Matthys P, Snoeck R. Reduced tumorigenicity and pathogenicity of cervical carcinoma SiHa cells selected for resistance to cidofovir. Mol Cancer 2013;12:158. [PMID: 24325392 DOI: 10.1186/1476-4598-12-158] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
29 Liu Y, Chen H, Sun Z, Chen X. Molecular mechanisms of ethanol-associated oro-esophageal squamous cell carcinoma. Cancer Lett 2015;361:164-73. [PMID: 25766659 DOI: 10.1016/j.canlet.2015.03.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
30 Eli M, Li DS, Zhang WW, Kong B, Du CS, Wumar M, Mamtimin B, Sheyhidin I, Hasim A. Decreased blood riboflavin levels are correlated with defective expression of RFT2 gene in gastric cancer. World J Gastroenterol 2012; 18(24): 3112-3118 [PMID: 22791947 DOI: 10.3748/wjg.v18.i24.3112] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
31 He Z, Huang X, Ni Y, Shi P, Wang Z, Han W, Hu Q. Functional toll-like receptor 3 expressed by oral squamous cell carcinoma induced cell apoptosis and decreased migration. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 2014;118:92-100. [DOI: 10.1016/j.oooo.2014.03.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
32 Mishra V, Pathak C. Human Toll-Like Receptor 4 (hTLR4): Structural and functional dynamics in cancer. International Journal of Biological Macromolecules 2019;122:425-51. [DOI: 10.1016/j.ijbiomac.2018.10.142] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
33 Zu Y, Ping W, Deng T, Zhang N, Fu X, Sun W. Lipopolysaccharide-induced toll-like receptor 4 signaling in esophageal squamous cell carcinoma promotes tumor proliferation and regulates inflammatory cytokines expression. Dis Esophagus 2017;30:1-8. [PMID: 27061118 DOI: 10.1111/dote.12466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
34 Sheikh A, Taube J, Greathouse KL. Contribution of the Microbiota and their Secretory Products to Inflammation and Colorectal Cancer Pathogenesis: The Role of Toll-like Receptors. Carcinogenesis 2021:bgab060. [PMID: 34218275 DOI: 10.1093/carcin/bgab060] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Le Noci V, Bernardo G, Bianchi F, Tagliabue E, Sommariva M, Sfondrini L. Toll Like Receptors as Sensors of the Tumor Microbial Dysbiosis: Implications in Cancer Progression. Front Cell Dev Biol 2021;9:732192. [PMID: 34604233 DOI: 10.3389/fcell.2021.732192] [Reference Citation Analysis]
36 Hübbe ML, Jæhger DE, Andresen TL, Andersen MH. Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade. Front Immunol 2020;11:578349. [PMID: 33101304 DOI: 10.3389/fimmu.2020.578349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Khan AA, Shrivastava A, Khurshid M. Normal to cancer microbiome transformation and its implication in cancer diagnosis. Biochim Biophys Acta 2012;1826:331-7. [PMID: 22683403 DOI: 10.1016/j.bbcan.2012.05.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
38 Jones JO, Moody WM, Shields JD. Microenvironmental modulation of the developing tumour: an immune-stromal dialogue. Mol Oncol 2021;15:2600-33. [PMID: 32741067 DOI: 10.1002/1878-0261.12773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Ridnour LA, Cheng RY, Switzer CH, Heinecke JL, Ambs S, Glynn S, Young HA, Trinchieri G, Wink DA. Molecular pathways: toll-like receptors in the tumor microenvironment--poor prognosis or new therapeutic opportunity. Clin Cancer Res 2013;19:1340-6. [PMID: 23271799 DOI: 10.1158/1078-0432.CCR-12-0408] [Cited by in Crossref: 93] [Cited by in F6Publishing: 53] [Article Influence: 9.3] [Reference Citation Analysis]
40 Han S, Xu W, Wang Z, Qi X, Wang Y, Ni Y, Shen H, Hu Q, Han W. Crosstalk between the HIF-1 and Toll-like receptor/nuclear factor-κB pathways in the oral squamous cell carcinoma microenvironment. Oncotarget 2016;7:37773-89. [PMID: 27191981 DOI: 10.18632/oncotarget.9329] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
41 Nesteruk K, Spaander MCW, Leeuwenburgh I, Peppelenbosch MP, Fuhler GM. Achalasia and associated esophageal cancer risk: What lessons can we learn from the molecular analysis of Barrett's-associated adenocarcinoma? Biochim Biophys Acta Rev Cancer 2019;1872:188291. [PMID: 31059738 DOI: 10.1016/j.bbcan.2019.04.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
42 Dai Q, Li XP, Chai L, Long HA, Yang ZH. Polymorphisms of Toll-like receptor 9 are associated with nasopharyngeal carcinoma susceptibility. Tumor Biol 2014;35:3247-53. [DOI: 10.1007/s13277-013-1424-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
43 Mai CW, Kang YB, Pichika MR. Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers. Onco Targets Ther. 2013;6:1573-1587. [PMID: 24235843 DOI: 10.2147/ott.s50838] [Cited by in Crossref: 13] [Cited by in F6Publishing: 34] [Article Influence: 1.4] [Reference Citation Analysis]
44 Pandey S, Singh S, Anang V, Bhatt AN, Natarajan K, Dwarakanath BS. Pattern Recognition Receptors in Cancer Progression and Metastasis. Cancer Growth Metastasis 2015;8:25-34. [PMID: 26279628 DOI: 10.4137/CGM.S24314] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 5.9] [Reference Citation Analysis]
45 Zandi Z, Kashani B, Poursani EM, Bashash D, Kabuli M, Momeny M, Mousavi-pak SH, Sheikhsaran F, Alimoghaddam K, Mousavi SA, Ghaffari SH. TLR4 blockade using TAK-242 suppresses ovarian and breast cancer cells invasion through the inhibition of extracellular matrix degradation and epithelial-mesenchymal transition. European Journal of Pharmacology 2019;853:256-63. [DOI: 10.1016/j.ejphar.2019.03.046] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
46 Urban-Wojciuk Z, Khan MM, Oyler BL, Fåhraeus R, Marek-Trzonkowska N, Nita-Lazar A, Hupp TR, Goodlett DR. The Role of TLRs in Anti-cancer Immunity and Tumor Rejection. Front Immunol 2019;10:2388. [PMID: 31695691 DOI: 10.3389/fimmu.2019.02388] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 22.0] [Reference Citation Analysis]
47 Hasnat S, Hujanen R, Nwaru BI, Salo T, Salem A. The Prognostic Value of Toll-Like Receptors in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. Int J Mol Sci 2020;21:E7255. [PMID: 33008143 DOI: 10.3390/ijms21197255] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Ohadian Moghadam S, Nowroozi MR. Toll‐like receptors: The role in bladder cancer development, progression and immunotherapy. Scand J Immunol 2019;90. [DOI: 10.1111/sji.12818] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
49 Linnebacher M, Maletzki C, Klier U, Klar E. Bacterial immunotherapy of gastrointestinal tumors. Langenbecks Arch Surg 2012;397:557-68. [PMID: 22189906 DOI: 10.1007/s00423-011-0892-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
50 Muresan XM, Bouchal J, Culig Z, Souček K. Toll-Like Receptor 3 in Solid Cancer and Therapy Resistance. Cancers (Basel) 2020;12:E3227. [PMID: 33147700 DOI: 10.3390/cancers12113227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
51 Jiang J, Dong L, Qin B, Shi H, Guo X, Wang Y. Decreased expression of TLR7 in gastric cancer tissues and the effects of TLR7 activation on gastric cancer cells. Oncol Lett 2016;12:631-6. [PMID: 27347192 DOI: 10.3892/ol.2016.4617] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
52 Chen G, Xu M, Chen J, Hong L, Lin W, Zhao S, Zhang G, Dan G, Liu S. Clinicopathological Features and Increased Expression of Toll-Like Receptor 4 of Gastric Cardia Cancer in a High-Risk Chinese Population. J Immunol Res 2018;2018:7132868. [PMID: 29670922 DOI: 10.1155/2018/7132868] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
53 Pandey N, Chauhan A, Jain N. TLR4 Polymorphisms and Expression in Solid Cancers. Mol Diagn Ther 2018;22:683-702. [PMID: 30311146 DOI: 10.1007/s40291-018-0361-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
54 Mohamed FE, Al-Jehani RM, Minogue SS, Andreola F, Winstanley A, Olde Damink SW, Habtesion A, Malagó M, Davies N, Luong TV. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2015;35:1063-1076. [PMID: 24990399 DOI: 10.1111/liv.12626] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
55 Li L, Cheng FW, Wang F, Jia B, Luo X, Zhang SQ. The activation of TLR7 regulates the expression of VEGF, TIMP1, MMP2, IL-6, and IL-15 in Hela cells. Mol Cell Biochem 2014;389:43-9. [PMID: 24347177 DOI: 10.1007/s11010-013-1925-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
56 Zheng X, Li S, Yang H. Roles of Toll-Like Receptor 3 in Human Tumors. Front Immunol 2021;12:667454. [PMID: 33986756 DOI: 10.3389/fimmu.2021.667454] [Reference Citation Analysis]
57 Shahanavaj K, Gil-Bazo I, Castiglia M, Bronte G, Passiglia F, Carreca AP, del Pozo JL, Russo A, Peeters M, Rolfo C. Cancer and the microbiome: potential applications as new tumor biomarker. Expert Rev Anticancer Ther 2015;15:317-30. [PMID: 25495037 DOI: 10.1586/14737140.2015.992785] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
58 Kaur D, Arora C, Raghava GPS. Prognostic Biomarker-Based Identification of Drugs for Managing the Treatment of Endometrial Cancer. Mol Diagn Ther 2021;25:629-46. [PMID: 34155607 DOI: 10.1007/s40291-021-00539-1] [Reference Citation Analysis]
59 Han JH, Park SY, Kim JB, Cho SD, Kim B, Kim BY, Kang MJ, Kim DJ, Park JH, Park JH. TLR7 expression is decreased during tumour progression in transgenic adenocarcinoma of mouse prostate mice and its activation inhibits growth of prostate cancer cells. Am J Reprod Immunol 2013;70:317-26. [PMID: 23790156 DOI: 10.1111/aji.12146] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
60 Jia D, Yang W, Li L, Liu H, Tan Y, Ooi S, Chi L, Filion LG, Figeys D, Wang L. β-Catenin and NF-κB co-activation triggered by TLR3 stimulation facilitates stem cell-like phenotypes in breast cancer. Cell Death Differ 2015;22:298-310. [PMID: 25257174 DOI: 10.1038/cdd.2014.145] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
61 Koliaraki V, Henriques A, Prados A, Kollias G. Unfolding innate mechanisms in the cancer microenvironment: The emerging role of the mesenchyme. J Exp Med 2020;217:e20190457. [PMID: 32044979 DOI: 10.1084/jem.20190457] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
62 Gowing SD, Cool-Lartigue JJ, Spicer JD, Seely AJE, Ferri LE. Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence. Clin Exp Metastasis 2020;37:225-39. [PMID: 31975313 DOI: 10.1007/s10585-020-10018-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
63 Cheng D, Hao Y, Zhou W, Ma Y. Association between Toll-like receptor 3 polymorphisms and cancer risk: a meta-analysis. Tumour Biol 2014;35:7837-46. [PMID: 24819172 DOI: 10.1007/s13277-014-2049-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
64 Petes C, Odoardi N, Gee K. The Toll for Trafficking: Toll-Like Receptor 7 Delivery to the Endosome. Front Immunol 2017;8:1075. [PMID: 28928743 DOI: 10.3389/fimmu.2017.01075] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
65 Kashani B, Zandi Z, Karimzadeh MR, Bashash D, Nasrollahzadeh A, Ghaffari SH. Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers. Immunol Res 2019;67:505-16. [DOI: 10.1007/s12026-019-09113-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]